Sinonasal teratocarcinosarcoma: a case report

Abstract

BackgroundSinonasal teratocarcinosarcoma is a rare and aggressive malignancy with histological features of both carcinosarcoma and teratoma. The optimal management of this malignancy is unclear, with most patients being managed by a combination of surgery and radiotherapy.Case presentationWe describe an 83-year-old white woman with sinonasal teratocarcinosarcoma of her left nasal cavity treated with surgical debulking initially with radiological evidence of residual disease which was treated with radiotherapy (60 Gy in 30 fractions). A follow-up examination at 2 years showed no evidence of recurrence.ConclusionsIn cases of sinonasal teratocarcinosarcoma with residual disease post-surgery, radiotherapy alone can be an effective option.

The first case report of primary thyroid teratocarcinosarcoma: An analog to sinonasal teratocarcinosarcoma

“…It arises commonly from the nasal cavity, paranasal sinuses with some reported cases arising from the nasopharynx and oral cavity. 2 – 5 Majority of the cases reported exhibit male predominance with most of them found in the adult population of above 35 years. 6 , 7 Histologically, teratocarcinosarcomas show heterogeneous morphology with variable proportions of benign and malignant epithelial, mesenchymal, and neuroepithelial elements.…”

Sinonasal teratocarcinosarcoma: a case report and literature review

“… 6 , 7 The incidence is relatively low, with fewer than 150 cases reported worldwide and only ∼10 cases in China. We reviewed the literature from 1968 to 2020, and 107 SNTCS cases were identified during this period ( Table 1 ) 5 , 8 – 22 .…”

Sinonasal teratocarcinosarcoma treated with surgery followed by volumetric modulated radiotherapy: a case report with review of literature

“…However, whether this clinical advantage of IMRT can be extrapolated to SNTCS is a matter of debate as there is no trial suggesting the use of IMRT in SNCTS primarily because of the rarity of the tumor. Reports using IMRT in SNTCS with a dose prescription 60–66 Gy, reported local control ranging between 2 and 3.5 years [14-16].…”